NeuroNOS

About

Funding history · 1 round · $2.0M total

Q&A

What is NeuroNOS's primary focus?

NeuroNOS is a biopharmaceutical company developing a novel drug for Autism Spectrum Disorder (ASD) and other neurological conditions. Their small-molecule therapy aims to regulate nitric oxide (NO) levels in the brain to address underlying biological mechanisms of ASD.

What is the current status of NeuroNOS?

NeuroNOS was acquired in January 2026.

How much funding has NeuroNOS raised in total?

NeuroNOS has raised a total of $2,000,000.

When did NeuroNOS complete its Seed funding round?

In March 2025, NeuroNOS completed a Seed funding round, raising $2,000,000 from private investors.

Who is the Chief Executive Officer of NeuroNOS?

Amir Avniel serves as the Chief Executive Officer of NeuroNOS.

Who is the Chief Scientific Officer of NeuroNOS?

Prof. Haitham Amal is the Chief Scientific Officer of NeuroNOS, appointed in 2023.

What is the origin of NeuroNOS's core technology?

NeuroNOS's small-molecule therapy is based on technology from the Hebrew University of Jerusalem.

Team · 8

Prof. Haitham Amal

Founder · Chief Scientific Officer

Amir Avniel

Chief Executive Officer

Meital Hatan

Head of R&D Program Management

John E. Jett

Head of Clinical Development

Bo Kim

Head of Regulatory Affairs and Quality Assurance

Melissa Joseph

Senior Pharmaceutical Development Consultant

Prof. Dan Shechtman

Scientific Advisory Board Member

Prof. Roger D. Kornberg

Scientific Advisory Board Member

Sectors & technology